IN THIS ISSUE

Preetinder S. Gill
These tools, often adopted by other industries, can help insurers improve health care delivery
Frank Diamond
A controversial study challenges backers to prove that these technologies are cost-effective
Gregory K. Bell, PhD
Shannon A. Baumann, MS
An MCO with an integrated medical and pharmacy benefit management system can overcome the challenges associated with this costly category
Peer-Reviewed
Navin K. Singh, MD
Nancy L. Reaven, MA
Susan E. Funk, MBA

There was little difference between the options in terms of the frequency and cost of return visits. Patients receiving one-stage reconstructions returned slightly less often for breast-related services during the first 18 months after reconstruction, but the difference was not statistically significant.

Legislation & Regulation
John Carroll
The SGR, ill-conceived and continually bypassed, may be nearing the end of its pathetic, useless life
Plan Watch
Frank Diamond

The insurer studies exactly what works and why in studying two programs that battle diabetes

Tomorrow's Medicine
Thomas Morrow, MD

This population can benefit from Juxtapid and Kynamro, but the cost is not addressed by health reform